Association between ischemia-modified albumin and oxidative stress markers in patients with metabolic syndrome
Mustafa Özbek1, Evrim Çakir1, Nujen Çolak1, Erman Çakal1, Yüksel Aliyazicioglu1,2, Ahmet Mentese1,2, Ibrahim Turan1,2 & Tuncay Delibasi1
Objective: The aim of this study was to determine the change in serum ischemia-modified albumin (IMA) level and oxidative stress markers (total antioxidant status, TAS, total oxidant status, TOS) in patients with metabolic syndrome (metS).
Research design and methods: We studied 52 metS patients (56.74±12.75 mean age), and 36 control subjects (54.47±6.52 mean age). The presence of metS was diagnosed according to National Cholesterol Education Program Adults Treatment Panel III (NCEP-ATP III). We measured serum IMA, TAS, TOS, and biochemical parameters in patients with metS, and control subjects.
Results: No statistically significant difference was determined for serum IMA levels, in metS patients and control group (0.264±0.053, and 0.27±0.049 respectively) (P=0.208). There was no statistically significant difference between TAS and TOS levels in metS patients (2.18±1.20, and 1.46±0.82, respectively), and in control subjects (1.96±0.46, and 1.79±0.82 respectively) (P=0.305, and 0.079). No statistically significant difference was determined for serum IMA levels in diabetic metS and control group (0.27±0.045, and 0.26±0.055, respectively) (P=0.533). Serum TOS levels were significantly higher in patients with diabetic metS than in control subjects (1.31±0.41, and 0.75±0.95, respectively) (P<0.023).
Conclusion: Results of our study revealed that IMA, TAS, and TOS levels in patients with metS are not different from healthy controls. Further studies are required to investigate the relation between the value of IMA and oxidative stress markers in patients with metabolic syndrome.